EcoDrugPlus

4-Hydroxyphenylpyruvate Dioxygenase-Like

Ensembl ID : ENSCSEG00000008031
Gene Symbol: LOC103396905
3 Cross references
206 Possible Orthologues:

40s Ribosomal Protein S16

Ensembl ID : ENSCSEG00000004450
Gene Symbol: LOC103382555
3 Cross references
268 Possible Orthologues:

40s Ribosomal Protein S16

Ensembl ID : ENSCSEG00000004454
Gene Symbol: LOC103382554
3 Cross references
268 Possible Orthologues:

40s Ribosomal Protein S19

Ensembl ID : ENSCSEG00000012783
Gene Symbol: LOC103394163
2 Cross references
288 Possible Orthologues:

40s Ribosomal Protein S19-Like

Ensembl ID : ENSCSEG00000014287
Gene Symbol: LOC103388963
3 Cross references
321 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSCSEG00000015086
Gene Symbol: LOC103393683
4 Cross references
516 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSCSEG00000005869
Gene Symbol: NT5E
4 Cross references
190 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCSEG00000002415
Gene Symbol: HTR1B
2 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSCSEG00000014247
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSCSEG00000000435
Gene Symbol: LOC103386587
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSCSEG00000016449
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSCSEG00000003580
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).